1Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Engl J Med 1999;341:556-562.
2Centers for Disease Control and Prevention. Recommendation for prevention and control of hepatits C (HCV) infection and HCV-related chronic disease. MMWRMob Mortal Wkly Rep 1998;47(191):1-38.
3Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
4Sulkowski MS, editor. Hepatitis for the new millennim. Baltimore: Johns Hopkins University School of Medicine, 1999.
5National Institutes of Health. Consensus Develoment Conference Panel statement: management of hepatis C. Hepatology 1997;26 (suppl 1):2S-10S.
6Short LJ, Bell DM. Risk ofoccupational infection with bloodborne pathogens in operating and delivery room settings. Am J Infect Control 1993;21:343-350.
7Owens DK, Nease RF. Occupational exposure to human immunodeficienry virus and hepatitis B virus: a comparative analysis of risk. Am J Med 1997;92:503-512.
8Reginier SJ. ACS/CDS meeting explores risks of bloodborne pathogens. Bull Am Coll Surg 1994;79:30-38.
9Puro v, Petrosillo N, tppolito G. Risk of hepatitis C seroconversion aher occupational exposures in health care workers. Am J Infect Control 1995;23:273-277.
10Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus rivavirin for 48 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-1432.
